SNAP-8
Acetyl Octapeptide-3
SNAP-8 is a synthetic octapeptide that mimics the N-terminal region of SNAP-25 to competitively inhibit SNARE complex formation, reducing acetylcholine release at neuromuscular junctions and thereby decreasing muscle contractions that cause dynamic facial wrinkles. It is marketed as a topical cosmetic ingredient for wrinkle reduction.
Last updated: 2026-03-13
Safety Summary
SNAP-8 has an excellent topical safety profile. The CIR (Cosmetic Ingredient Review) assessed acetyl hexapeptide-8 (the closely related 6-amino-acid analog) and found it safe for topical cosmetic use at concentrations up to 0.005%. Clinical studies (up to 14 weeks) reported no systemic adverse events and good tolerability. No serious adverse events have been attributed to topical SNAP-8 in published trials or pharmacovigilance databases (FAERS, EudraVigilance). No evidence of tolerance, tachyphylaxis, withdrawal effects, or rebound phenomena. No genotoxicity or carcinogenicity signals. Injectable use has NO published safety data and community sources warn of risks including infection, localized redness, swelling, and hard nodule formation, likely due to the peptide not being formulated for parenteral administration.
Known Side Effects
Rare (<1%)
Rare
Unknown (injectable use not formally studied)
Who Should NOT Use This
No clinical safety data supports injectable administration. Risk of infection, nodule formation, and unknown systemic effects. Community sources explicitly warn against injection.
Standard cosmetic precaution. Patch test recommended before first use.
Standard dermatologic caution - avoid applying to wounds or compromised skin barrier. May lead to unintended systemic absorption or irritation.
Not specifically studied in pregnancy or pediatric populations. Systemic absorption from topical use is minimal, but standard caution applies. Consult physician.
Talk to Your Doctor
Before considering SNAP-8, discuss it with your healthcare provider. Ask about potential interactions with your current medications, whether it is appropriate for your health conditions, and what monitoring may be needed.
Sources: [1-8]
Evidence Assessment
Evidence tier 5 (preclinical/in vitro with very limited human data). Extensive in vitro data exists regarding its SNARE-inhibiting mechanism. However, human evidence is entirely limited to small (n=15-30), open-label, industry-sponsored cosmetic trials of topical formulations, all using combination products rather than SNAP-8 alone. No formal pharmaceutical Phase II/III trials exist. No large randomized controlled trials, no FDA approval. Evidence quality is rated 'very low' by standard grading criteria due to high risk of bias, small sample sizes, industry sponsorship, and lack of blinding.
1An Open Label Clinical Trial of a Peptide Treatment Serum and Supporting Regimen Designed to Improve the Appearance of Aging Facial Skin
Draelos ZD, Kononov T, Fox T - Journal of Drugs in Dermatology (2016) - Open-label, single-center clinical usage study - 29
Statistically significant improvements at week 14 in facial lines, wrinkles, eye lines, and eye wrinkles versus baseline. Improvements also reported for skin smoothness, firmness, radiance, and overall appearance. Well tolerated with no adverse events reported.
Limitations: Open-label (no blinding), no placebo control, small sample size (n=29), multi-peptide product (not SNAP-8 alone - also contained other peptides and GABA), specific SNAP-8 concentration not disclosed, industry-related, no quantitative effect sizes or confidence intervals reported.
2Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term ActivitiesPMID 39082657
Shin JY et al. - Annals of Dermatology (2024) - Comparative clinical study (microneedle patch vs placebo patch) - 24
Significant improvements in periorbital wrinkle depth and skin elasticity versus placebo microneedle patch. Dissolving microneedle patch containing SNAP-8 showed anti-wrinkle efficacy with good safety profile.
Limitations: Small sample size (n=24), single-center, combination product (microneedle delivery + peptide), short duration.
3Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical studyPMID 31134751
Avcil M et al. - Not specified in raw data (2020) - Monocentric clinical study - 24
HA microneedle patch with SNAP-8 and other peptides showed 25.8% wrinkle depth reduction over 12 weeks.
Limitations: Open-label, monocentric, combination product (not SNAP-8 alone), small sample size.
4Topical Acetyl Hexapeptide-8 for BlepharospasmNCT01750346
Not reported - ClinicalTrials.gov registry entry - Registry entry (no posted results)
No results posted. Registry entry for topical acetyl hexapeptide-8 (note: this is the 6-AA analog Argireline, not SNAP-8 itself, but closely related) to treat blepharospasm.
Limitations: No results published. No protocol details available. Pertains to Argireline (AHP-8) rather than SNAP-8 specifically.
5Method development for acetyl octapeptide-3 analysis by liquid chromatography-tandem mass spectrometry
Not extracted - Journal of Analytical Science and Technology (2020) - Analytical method development
Developed LC-MS/MS method for quantifying acetyl octapeptide-3 (SNAP-8). Confirms molecular characterization. MW ~1075 Da.
Limitations: Analytical study, not a clinical efficacy trial.
6Acetyl Hexapeptide-8 in Cosmeceuticals - A Review of Skin Permeability and Efficacy
Not extracted - International Journal of Molecular Sciences (MDPI) (2025) - Review article
Comprehensive review of acetyl hexapeptide-8 and related peptides (including SNAP-8). Notes limited skin permeability and expected low systemic bioavailability. Reports SNAP-8 as designed to have improved efficacy over Argireline. No large RCTs identified for SNAP-8 specifically.
Limitations: Review article. Focused primarily on Argireline with SNAP-8 as a comparator. Industry-connected sources for some efficacy claims.
7Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A Review
Not extracted - Biomolecules (MDPI) (2025) - Review article
Reviews SNAP-8 mechanism as SNARE-complex interfering peptide. Notes in vitro evidence for collagen synthesis stimulation. Characterizes SNAP-8 as a cosmetic/dermatological peptide with limited systemic data. No peer-reviewed evidence for systemic effects on non-dermatological body systems.
Limitations: Review article, not primary research.
8Safety Assessment of Acetyl Hexapeptide-8 as Used in Cosmetics
Cosmetic Ingredient Review (CIR) Expert Panel - International Journal of Toxicology (CIR report) (2012) - Safety assessment / regulatory review
CIR concluded acetyl hexapeptide-8 (closely related to SNAP-8) is safe for topical cosmetic use at concentrations up to 0.005%. No genotoxicity, no carcinogenicity signals, no systemic toxicity at cosmetic use levels. HRIPT (Human Repeat Insult Patch Test) negative for sensitization.
Limitations: Assessment pertains to the 6-amino-acid Argireline analog, not SNAP-8 specifically, though they are structurally similar. Cosmetic concentrations only.